Breaking News Instant updates and real-time market news.

HRL

Hormel Foods

$42.15

(0.00%)

, AGN

Allergan

$129.65

(0.00%)

09:40
06/25/19
06/25
09:40
06/25/19
09:40

Unusually active option classes on open June 25th

Unusual total active option classes on open include: Hormel Foods (HRL), Allergan (AGN), Bausch Health (BHC), GrubHub (GRUB), Philip Morris (PM), National Oilwell (NOV), Riot Blockchain (RIOT), Fedex (FDX), Direxion Junior Gold (JNUG), and Activision Blizzard (ATVI).

HRL

Hormel Foods

$42.15

(0.00%)

AGN

Allergan

$129.65

(0.00%)

BHC

Bausch Health

$23.76

(0.00%)

GRUB

GrubHub

$72.05

(0.00%)

PM

Philip Morris

$77.83

(0.00%)

NOV

National Oilwell

$21.28

(0.00%)

RIOT

Riot Blockchain

$3.05

(0.00%)

FDX

FedEx

$160.88

(0.00%)

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$12.73

(0.00%)

ATVI

Activision Blizzard

$47.16

(0.00%)

  • 25

    Jun

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 30

    Jul

  • 30

    Jul

  • 31

    Jul

  • 27

    Aug

  • 13

    Nov

HRL Hormel Foods
$42.15

(0.00%)

06/13/19
FBCO
06/13/19
NO CHANGE
FBCO
Tyson plant-based launch not big threat to Beyond Meat, says Credit Suisse
Credit Suisse analyst Robert Moskow says this morning's launch of plant-based chicken nuggets and patties and hybrid beef-plant burgers and sausages supports his positive view on Tyson Foods (TSN). Perdue and Hormel Foods (HRL) have also signaled similar intentions to pursue hybrid meats, Moskow tells investors in a research note. The analyst, however, does not view Tyson's hybrid burgers as a major threat to Beyond Meat (BYND). Beyond's burger products are "more revolutionary and broader" in terms of potential consumer appeal, contends Moskow. Although competing hybrid burgers offer less saturated fat than the 100% plant-based products from Beyond and Impossible, "they simply don't taste as good in our experience," writes the analyst. Shares of Beyond Meat are down $1.04 to $140.93 in early trading while Tyson Foods is up $1.92 to $83.82.
04/23/19
04/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Hormel Foods (HRL) downgraded to Sell from Neutral at Goldman Sachs and to Underweight from Neutral at JPMorgan. 2. Digital Realty (DLR) downgraded to Hold from Buy at Jefferies with analyst Jonathan Petersen saying market absorption numbers from datacenterHawk suggest a leasing quarter even worse than Q4 of 2018 for the data center real estate investment trusts. 3. PSEG (PEG) downgraded to Neutral from Overweight at JPMorgan with analyst Christopher Turnure saying now that zero emission credits have been formally awarded, the he expects PJM capacity market reform driven-uncertainty to continue near-term or longer if the Federal Energy Regulatory Commission fails to approve a revised methodology soon. He sees limited near-term upside in PSEG shares. 4. Fortis (FTS) downgraded to Market Perform from Outperform at Raymond James. 5. Crocs (CROX) downgraded to Neutral from Overweight at Piper Jaffray with analyst Erinn Murphy saying the "runway for significant share appreciation becomes more difficult from here." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/23/19
SPHN
05/23/19
NO CHANGE
Target $37
SPHN
Equal Weight
African swine fever worries could pressure Hormel after earnings, says Stephens
Stephens analyst Ben Bienvenu noted that Hormel Foods reported Q2 results that were slightly ahead of expectations, but its FY19 EPS guidance was softer than consensus estimates. Comparing guidance to consensus, however, is complicated by the fact that some analysts were accounting for the sale of Cytosport in their estimates, while others did not, according to Bienvenu. While he keeps an Equal Weight rating on Hormel shares and is reviewing his estimate, the analyst said that management's mention of African swine fever uncertainty could pressure the shares today. In pre-market trading, Hormel shares are down $1.50, or 4%, to $37.99.
06/12/19
EDJN
06/12/19
DOWNGRADE
EDJN
Hold
Hormel Foods downgraded to Hold from Buy at Edward Jones
Edward Jones analyst John Boylan downgraded Hormel Foods to Hold from Buy.
AGN Allergan
$129.65

(0.00%)

06/25/19
WELS
06/25/19
NO CHANGE
WELS
Outperform
Deals with premiums like Allergan's 'rarely killed,' says Wells Fargo
After Abbvie (ABBV) announced an agreement to acquire Allergan (AGN) for $120 per share of cash and a remaining $68 in AbbVie shares, Wells Fargo analyst David Maris said he views the deal as a good alternative for Allergan versus the current share price, but he is not convinced its a better long term alternative given the eventual biosimilar threat to Abbvie's blockbuster drug Humira. With that said, Maris tells investors that "deals at such premiums are rarely killed because of a bad strategic fit or longer -term value outlook in the absence of other bidders." Though he would not completely rule out an activist investor disrupting the deal, he thinks it is unlikely given there has been a strategic review of the company for some time. Maris, who said he thinks the deal could go through, keeps an Outperform rating on Allergan shares.
06/25/19
PIPR
06/25/19
NO CHANGE
PIPR
Neutral
Piper says 'willing to listen' to AbbVie reasoning for Allergan acquisition
Ahead of the call to discuss AbbVie's (ABBV) planned $63B acquisition of Allergan (AGN), Piper Jaffray analyst Christopher Raymond said his first reaction to the deal could be summed up with the phrase "two turkeys don't make an eagle," but he is "willing to listen" despite his skepticism about the transaction. Though he cannot say he is "excited at the prospect of AbbVie entering the field of medical aesthetics," EPS accretion of 10% in year one and over 20% at peak, and the potential for meaningful deleveraging and cost cutting, has his attention, Raymond said. He keeps a Neutral rating on AbbVie based on his initial reaction to the deal announcement.
06/25/19
MZHO
06/25/19
NO CHANGE
Target $171
MZHO
Buy
Allergan price target lowered to $171 from $194 at Mizuho
Mizuho analyst Irina Koffler lowered her Botox Cosmetic and CoolSculpt estimates after conducting a survey of 20 dermatologists and plastic surgeons, who gave the impression that that the Botox franchise will be pressured by Evolus (EOLS) and other new entrants. Koffler cut her price target on Allergan shares to $171 from $194 based on the lowered estimates, but maintains a Buy rating on the stock, stating that it is "widely expected" that the company will make a strategic announcement that begins the preliminary work of separating the company in the next 1-2 months.
06/25/19
LEER
06/25/19
NO CHANGE
LEER
Outperform
Bid of $188 for Allergan 'too low,' others may pursue as well, says SVB Leerink
SVB Leerink analyst Marc Goodman is not surprise that one of the large pharma companies has made a bid on Allergan (AGN) given the multi-year stock weakness. However, he believes a $188 price is "too low," as he "can't believe that Allergan is not being taken out at least at $200," which "begs the question" whether this was a process or is AbbVie (ABBV) "opportunistically pursuing a wounded stock." If it is the latter, Goodman believes this bid could initiate others to pursue Allergan as well. He has an Outperform rating on Allegan's shares.
BHC Bausch Health
$23.76

(0.00%)

05/17/19
WELS
05/17/19
NO CHANGE
WELS
Underperform
Bausch Q1 results similar to old Valeant business model, says Wells Fargo
Wells Fargo analyst David Maris says Bausch Health Companies' Q1 results demonstrate why the company reminds him a lot of the old Valeant and its price and deal driven model. The analyst adds that while some point to better than expected EBITDA, he sees low growth and high debt. Further, how price and deals contributed to Bausch's growth in Q1 is a reminder that "the more things have changed, the more they stay the same," Maris tells investors in a research note. In the press release, Bausch led with how Xifaxan grew 11%, but overall revenue growth of just 1% is not mentioned until the bottom of the press release, Maris points out. He keeps an Underperform rating on Bausch Health shares with a $9 price target.
06/20/19
WELS
06/20/19
NO CHANGE
Target $9
WELS
Underperform
One of Bausch's key new drugs already facing generic challenge, says Wells Fargo
Wells Fargo analyst David Maris noted that an update posted on June 18 by the FDA revealed that a Paragraph IV challenge of Bausch Health's Bryhali was filed on March 20. The analyst, who explained that a Paragraph IV filing is made when a generic filer asserts either non-infringement or invalidity of branded product patents, called Bryhali one of Bausch's "key new drugs," noting that the company included it in what it has dubbed its "Significant Seven" products. A Paragraph IV filing does not mean a generic is imminent, said Maris, who also noted that such filings often result in settlements. The analyst, who said he is awaiting a reply from Bausch about this situation and whether it has sued the filing company, keeps an Underperform rating on Bausch Health shares.
06/11/19
PIPR
06/11/19
NO CHANGE
Target $29
PIPR
Overweight
Piper Jaffray stays bullish on Bausch Health after analyzing volume trends
Piper Jaffray analyst David Amsellem stays bullish on shares of Bausch Health Companies after taking a closer look at volume trends for key new additions to the company's portfolio, such as Trulance and Bryhali. The trajectories on the whole are favorable through May, Amsellem tells investors in a research note. The analyst believes Bausch "continues to stand apart from the group of highly levered companies in the broader specialty pharma/generics space." This is due to the company's high visibility into "meaningful" longer-term EBITDA growth, says Amsellem, who keeps an Overweight rating on the shares with a $29 price target.
06/11/19
LEHM
06/11/19
NO CHANGE
Target $28
LEHM
Overweight
Bausch Health transferred with an Overweight rating at Barclays
Barclays analyst Balaji Prasad took over coverage of Bausch Health Companies and keep an Overweight rating on the shares with a reduced price target of $28.
GRUB GrubHub
$72.05

(0.00%)

06/25/19
SBSH
06/25/19
UPGRADE
Target $91
SBSH
Buy
Citi sees five reasons to be bullish, upgrades GrubHub to Buy
As previously reported, Citi analyst Mark May upgraded GrubHub (GRUB) to Buy from Neutral and increased his price target on the stock to $91 from $75, citing five primary factors he sees to be more bullish on the stock. Those include data that suggests that GrubHub may be in early tests with McDonald's (MCD), Starbucks (SBUX) and other large chains; his belief that the stock's multiple will expands if investors reward the company for new chain deals; GrubHub's ability to grow Gross Food Sales in the 20% range, which should allow it to hit its Q4 EBITDA/order guidance; a new driver pay formula that could benefit margins; and robust growth in the overall online food delivery market.
06/25/19
SBSH
06/25/19
UPGRADE
SBSH
Buy
GrubHub upgraded to Buy from Neutral at Citi
06/14/19
DBAB
06/14/19
NO CHANGE
DBAB
Hold
GrubHub debt issue points to 'aggressive competition,' says Deutsche Bank
Deutsche Bank analyst Kunal Madhukar believes GrubHub's (GRUB) recent $500M debt issue likely signifies "more aggressive competition" within the food delivery space in the U.S. The food delivery market, especially outside of the large cities like New York and Chicago where GrubHub dominates, is growing largely because of the aggressive investments made by Doordash and Uber Eats (UBER) in the delivery infrastructure and in promotional offers, Madhukar tells investors in a research note. He keeps a Hold rating on GrubHub shares.
06/12/19
BOFA
06/12/19
NO CHANGE
Target $108
BOFA
Buy
Less competition for GrubHub amid Amazon Restaurants exit, says BofA/Merrill
Amazon's (AMZN) discontinuation of its U.S. restaurant delivery service removes the threat to GrubHub (GRUB) of Amazon expanding its online food delivery business organically, BofA/Merrill analyst Nat Schindler tells investors in a research note. Schindler notes that online food delivery is a large, fragmented, and rapidly evolving market with significant capital infusion from public and private investors, and Amazon may be shifting from "build" to "partner or buy" in this market. The analyst contends that while GrubHub has lost some market share recently, he sees growth as healthy overall, and says the disconnect between rising private valuations and recent declines in GrubHub's market cap may create an opportunity.
PM Philip Morris
$77.83

(0.00%)

05/28/19
SBSH
05/28/19
NO CHANGE
SBSH
Cigarette data from Nielsen 'dire,' industry data also 'very bad,' says Citi
Citi analyst Adam Spielman noted that Nielsen reported earlier today that cigarette industry volumes fell 11.2% in the four weeks ended May 18, noting that shares of Altria (MO), British American Tobacco (BTI) and Imperial (IMBBY) all fell following the "dire" data. Volumes in MSAi, the industry database that he regards as much more reliable than Nielsen, were down 6.4% in the same period, which Spielman said "is still a very bad figure, but it is a lot, lot better than the Nielsen one." Looking ahead, the analyst said he expects "gradually less bad" volumes in Nielsen in the rest of the year, though he noted that Altria has said it expects industry volumes to fall about 4%-5% this year and he forecasts a decline of about 6%. In late afternoon trading, Altria shares are down 4.5%, British American has declined over 4% and Philip Morris (PM) is down 5%.
05/23/19
05/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Horvers saying he believes the shares are undervalued and he sees potential upside to consensus estimates. 2. Philip Morris (PM) upgraded to Equal Weight from Underweight at Barclays with analyst Gaurav Jain saying unlike British American Tobacco (BTI), Philip Morris' Canadian subsidiary value is more than the value of the liability. 3. Booking Holdings (BKNG) upgraded to Buy from Neutral at Citi saying Booking's valuation, following the stock's underperformance this year, now better reflects the business slowdown it faces and is attractive on a cash flow basis. 4. Vertex (VRTX) assumed with a Buy from Neutral at Goldman Sachs with analyst Salveen Richter saying he believes the likely approval of the triple combination regimen in 2020 will extend Vertex's cystic fibrosis opportunity to ~90% of the market. 5. Ferrari (RACE) upgraded to Outperform from In Line at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/23/19
LEHM
05/23/19
UPGRADE
Target $82
LEHM
Equal Weight
Barclays upgrades Philip Morris to Equal Weight, boosts target to $82
Barclays analyst Gaurav Jain upgraded Philip Morris to Equal Weight from Underweight and raised his price target for the shares to $82 from $67. Unlike British American Tobacco (BTI), Philip Morris' Canadian subsidiary value is more than the value of the liability, Jain tells investors in a research note. The analyst expects Philip Morris will continue to trade at a premium valuation to peers given its higher exposure to reduced risk products, higher return on invested capital, better management and stronger brands.
06/19/19
WELS
06/19/19
NO CHANGE
Target $100
WELS
Outperform
Philip Morris recent selloff 'unjustified,' says Wells Fargo
Wells Fargo analyst Bonnie Herzog reiterates her bullish call on Philip Morris and believes the recent selloff in the stock is "unjustified." The analyst sees this as an opportunity for long-term investors to enter or build positions in what she believes is one of the "most attractive CPG stocks" in terms of growth prospects and yield characteristics. Herzog reiterates an Outperform rating and $100 price target on the shares.
NOV National Oilwell
$21.28

(0.00%)

04/16/19
RHCO
04/16/19
NO CHANGE
Target $24
RHCO
Hold
National Oilwell price target lowered to $24 from $29 at SunTrust
SunTrust analyst Ken Sill lowered his price target on National Oilwell to $24 and kept his Hold rating after its below-consensus Q1 pre-announcement. The analyst states however that while he expects the management's outlook on its April 26th earnings call to be "cautious", he also believes that "most of the damage from the earnings miss has already been incurred." Sill adds that National Oilwell is typically a "late cycle play", stating that the company's "activity in North America is bottoming, while international activity, as measure by the rig count, has been better than expected".
02/11/19
RHCO
02/11/19
NO CHANGE
Target $29
RHCO
Hold
National Oilwell price target lowered to $29 from $40 at SunTrust
SunTrust analyst Ken Sill lowered his price target on National Oilwell to $29 and kept his Hold rating, saying the recovery of the company's business has been slow. The analyst notes that while the company's Rig Technology segment has turned the corner and the management's focus has fallen on its Completion/Production and Wellbore segments, revenue growth is likely to be contained by the recent oil price dip which pushed the bottom for offshore completions to Q1 or Q2 of 2019. Sill still sees some "modest growth" for National Oilwell, but not a return to that of a prior peak period.
01/17/19
STFL
01/17/19
NO CHANGE
STFL
Stifel lowers Oilfield Services and Equipment estimates
Stifel analyst Stephen Gengaro said he expects overall E&P capital spending to be about flat in the U.S. market and he cut his forecast for U.S. drilling and completion activity based on the current WTI crude oil strip. He lowered his U.S rig count projections by 50 to 1,050 rigs in 2019 and by 100 to 1,150 rigs in 2020 and he cut his 2019 EBITDA forecast by roughly 10% on average. Based on the changes in estimates, Gengaro lowered his earnings expectations for the majority of the names he covers and cut his price targets on several. Among the largest target changes, he lowered his price target on Core Laboratories (CLB) to $86 from $110, cut his target on Emerge Energy (EMES) to $3 from $5, reduced his target on Halliburton (HAL) to $37 from $45 and trimmed his target on Superior Energy (SPN) to $5 from $9. Others in the space that Gengaro covers include Baker Hughes (BHGE), DMC Global (BOOM), Civeo (CVEO), Keane Group (FRAC), FTS International (FTSI), Liberty Oilfield Services (LBRT), National Oilwell (NOV), Oil States (OIS), Pioneer Energy (PES), ProPetro Holding (PUMP), RPC, Inc. (RES), Schlumberger (SLB), U.S. Silica (SLCA), Smart Sand (SND), Solaris Oilfield (SOI), Tenaris (TS), Tetra Technologies (TTI) and Weatherford (WFT).
03/10/19
GSCO
03/10/19
INITIATION
Target $33
GSCO
Neutral
National Oilwell initiated with a Neutral at Goldman Sachs
Goldman Sachs started National Oilwell Varco with a Neutral rating and $33 price target.
RIOT Riot Blockchain
$3.05

(0.00%)

10/04/18
HCWC
10/04/18
NO CHANGE
Target $4
HCWC
Buy
Riot Blockchain price target lowered to $4 from $10 at H.C. Wainwright
H.C. Wainwright analyst Kevin Dede lowered his price target for Riot Blockchain to $4 from $10 but keeps a Buy rating on the shares. The "ugly ramifications" of Riot's CEO departure in early September compounded by an increasingly difficult bitcoin mining and pricing environment have temporarily upended the company's fundamental development, Dede tells investors in a research note partially titled "Industry Dynamics Strain a Temporarily Fractured Business Model." The analyst, however, sees a "silver lining" in Riot's focus and commitment to building its cryptocurrency trading platform, RiotX. Dede remains bullish on bitcoin's "eventuality in fulfilling its utilitarian currency potential."
04/05/19
HCWC
04/05/19
NO CHANGE
Target $5
HCWC
Buy
Riot Blockchain price target raised to $5 from $4 at H.C. Wainwright
H.C. Wainwright analyst Kevin Dede raised his price target for Riot Blockchain to $5 from $4 and keeps a Buy rating on the shares. While the company's full-year filing implies Q4 mining slowed, the "ramifications are deemed irrelevant" by the recent bitcoin pricing trend, Dede tells investors in a research note. The analyst believes that while the Riot Blockchain share price still appears clearly driven by bitcoin pricing, the company represents "far more than a simplistic crypto mining operation."
FDX FedEx
$160.88

(0.00%)

06/12/19
KEYB
06/12/19
NO CHANGE
Target $190
KEYB
Overweight
FedEx price target lowered to $190 from $215 at KeyBanc
KeyBanc analyst Todd Fowler lowered his price target for FedEx (FDX) to $190 from $215 ahead of Q4 to reflect trade uncertainty and some impact of the non-renewal of the U.S. domestic Express contract with Amazon (AMZN), partially offset by improved Ground margins, voluntary buyout benefits, and modest Freight contribution. The analyst reiterates an Overweight rating on the shares.
06/20/19
RAJA
06/20/19
NO CHANGE
Target $200
RAJA
Outperform
FedEx price target lowered to $200 from $215 at Raymond James
Raymond James analyst Patrick Tyler Brown lowered his price target for FedEx to $200 from $215, while reiterating an Outperform rating on the shares. While the analyst appreciates that the specter of slowing economic growth in Europe and Asia could continue to drive volume headwinds over coming quarters, he continues to believe that FedEx garners a "strong and highly idiosyncratic long-term growth profile," driven, in part, by his view that the TNT acquisition will eventually prove accretive. Moreover, on the Domestic front, Brown remains optimistic in the long-term earnings power of Ground and believes Freight, underpinned by the company's dominant terminal network can continue to drive earnings growth over freight cycles.
06/18/19
SPHN
06/18/19
NO CHANGE
Target $210
SPHN
Overweight
FedEx recent headlines like 'entering The Twilight Zone,' says Stephens
Stephens analyst Jack Atkins said he understands if FedEx (FDX) investors feel some headline fatigue given it seems like "entering The Twilight Zone" with news of an expansion to its Ground operating week, canceling bonuses, telling Amazon (AMZN) it wasn't interested in its U.S. Express package business and China having launched a probe all just within the last few weeks. While Atkins lowered his Q4 outlook for FedEx to reflect increased concern about global trade trends and deteriorating demand for global airfreight capacity, he also believes the bar is low and notes the stock is trading near trough valuations. Atkins keeps an Overweight rating and $210 price target on FedEx ahead of the company's Q4 report and expected FY20 guidance announcement on June 25.
06/11/19
FBCO
06/11/19
NO CHANGE
Target $184
FBCO
Outperform
FedEx price target lowered to $184 from $241 at Credit Suisse
Credit Suisse analyst Allison Landry lowered his price target for FedEx (FDX) to $184 from $241 in light of the deceleration in the U.S. and global macro and temporary volume and cost headwinds, including 7-day Ground and non-renewal of the Amazon (AMZN) Domestic Express contract. The analyst reiterates an Outperform rating on FedEx shares.
JNUG Direxion Daily Jr Gld Mnrs Bull 3X Shrs
$12.73

(0.00%)

ATVI Activision Blizzard
$47.16

(0.00%)

06/07/19
SBSH
06/07/19
INITIATION
Target $47
SBSH
Neutral
Activision Blizzard initiated with a Neutral at Citi
Citi analyst Jason Bazinet started Activision Blizzard with a Neutral rating and $47 price target. The analyst believes consensus estimates are at the right level and that the valuation looks fair at current share levels.
06/06/19
NOMU
06/06/19
INITIATION
Target $120
NOMU
Buy
Electronic Arts initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Andrew Marok last night initiated coverage of Electronic Arts (EA) with a Buy rating and $120 price target. The analyst also started Activision Blizzard (ATVI) with a Neutral rating. Electronic Arts is well positioned to capitalize on trends in the broader gaming industry, Marok tells investors in a research note. The company's subscription service is scaling well and is expanding to new platforms, adds the analyst. Further, he views Apex Legends as a new growth driver for EA.
06/06/19
06/06/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Outperform at Evercore ISI. 2. Chegg (CHGG) initiated with a Buy at Needham. 3. Cidara Therapeutics (CDTX) initiated with an Outperform at Oppenheimer. 4. Corteva (CTVA) initiated with a Market Perform at Bernstein. 5. Electronic Arts (EA) initiated with a Buy at Nomura Instinet while Activision Blizzard (ATVI) was initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/06/19
NOMU
06/06/19
INITIATION
Target $49
NOMU
Neutral
Activision Blizzard initiated with a Neutral at Nomura Instinet
Nomura Instinet analyst Andrew Marok last night initiated coverage of Activision Blizzard with a Neutral rating and $49 price target. The company's near-term release roadmap does not appear to provide many opportunities for "notable upside," especially at Blizzard, Marok tells investors in a research note. Outside of "dependable releases" such as the yearly Call of Duty title and semi-annual World of Warcraft expansion, Activision's frontline product pipeline is at a "low point," says the analyst. As such, he sees limited near-term catalysts for the shares.

TODAY'S FREE FLY STORIES

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.